| Ytd | 111.36% | |
| 1y | 78.72% |
| Open | 9.51 | Prev Close | 9.63 | Low | 9.23 | High | 9.87 | Mkt Cap | 85.56M |
| Vol | 96.28K | Avg Vol | 101.76K | EPS | -1.65 | P/E | N/A | Forward P/E | -31.85 |
| Beta | 0.92 | Short Ratio | 0.54 | Inst. Own | 16.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 7.85 | 200-d Avg | 6.79 | 1yr Est | 25.47 |
ECOR News
Recognition highlights Truvaga's combination of patented non-invasive vagus nerve stimulation techno
electroCore (NASDAQ:ECOR) lowers FY2026 sales outlook from $41.642 million to $41.600 million vs $41
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.33) per share which beat the analyst cons
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's
Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market
The publication in JAMA Network Open, titled, "Transcutaneous Electrical Nerve Stimulation and P
electroCore (NASDAQ:ECOR) affirms FY2026 sales outlook from $41.642 million to $41.642 million vs $4
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.59) per share which missed the analyst co
The publication reports results from a post-hoc analysis of 35 patients with chronic mTBI and PTSD.
U.S. Patent No. 12,208,263, entitled "Devices and Methods for Vagal Nerve Stimulation" was i
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.34) per share which beat the analyst cons
electroCore, Inc. (Nasdaq: ECOR) ("electroCore" or the "Company"), a bioelectronic t
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains electroCore (NASDAQ:ECOR) with a
electroCore, Inc. (Nasdaq: ECOR) ("electroCore" or the "Company"), a bioelectronic t
Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9
https://ppubs.uspto.gov/api/pdf/downloadPdf/12469610?requestToken=eyJzdWIiOiIzZTQ5MWI5NS0wZjI4LTQwYj
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.40) per share which met the analyst conse
electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, to
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.44) per share which missed the analyst co
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.47) per share which missed the analyst co
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates electroCore (NASDAQ:ECOR) with
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, tod
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, tod
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains electroCore (NASDAQ:ECOR) with a
The transaction has been unanimously approved by the boards of directors of both companies and is ex
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.31) per share which beat the analyst cons
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.38) per share which beat the analyst cons
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, is
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.53) per share which beat the analyst cons
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarte
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is estimated to report quarterly earni
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earn
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnin